SCHEMBL20090145

SCHEMBL20090145

O=P(c1ccccc1)(c1ccccc1)c1ccc2cc(-c3ccc4c5cc6ccccc6cc5c5nc6ccccc6n5c4c3)ccc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.41
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 5/20 0.41
KMT2A Q03164 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 4/20 0.36
POLB P06746 3/20 0.36
LMNA P02545 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TP53 P04637 1/20 0.36
MEN1 O00255 3/20 0.34
CAMKK1 Q8N5S9 2/20 0.34
CAMKK2 Q96RR4 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CASP1 P29466 1/20 0.34
CYP2C19 P33261 1/20 0.34
CASP7 P55210 1/20 0.34
TUBB4A P04350 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21164668 0.98 ALDH1A1 (0.41) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL19960303 0.96 HPGD (0.38) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090153 0.96 ALDH1A1 (0.44) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL14644083 0.96 ALDH1A1 (0.44) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL19960299 0.95 ALDH1A1 (0.41) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL15479213 0.94 KDM4E (0.45) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL15479210 0.94 KDM4E (0.45) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL19960264 0.93 ALDH1A1 (0.34) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL19960109 0.92 KDM4E (0.42) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL15479200 0.91 KDM4E (0.42) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same LG CHEM, LTD. (KR) 2019-07-16 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME CRY1, CRY2, PER2 HPGD 2982/4885ALDH1A1 750/4885KDM4E 1997/4885
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same CRY1, CRY2, PER2 HPGD 2982/4885ALDH1A1 750/4885KDM4E 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.